Shares in Ocular Therapeutix (NSDQ:OCUL) fell today after the ophthalmologic device developer posted 1st quarter earnings that missed expectations on Wall Street.
The Bedford, Mass.-based company posted losses of $16 million, or 58¢ per share, on sales of $475,000 for the 3 months ended March 31, seeing losses grow 47.8% while sales grew 14.2% compared with the same period last year.
Read the whole story on our sister site, Drug Delivery Business